Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
Semin Oncol. 2014 Feb;41(1):57-68. doi: 10.1053/j.seminoncol.2013.12.012. Epub 2013 Dec 12.
Locally advanced non-small cell lung cancer (LA-NSCLC) is a heterogeneous disease, encompassing stage IIIA, for which surgery in combination with chemotherapy and/or radiation therapy (RT) represents a potential treatment approach for select patients, and stage IIIB, for which chemoradiation represents the standard of care. Recent advances in systemic cytotoxic and molecularly targeted therapies coupled with technologic innovations in radiotherapy have the potential to improve outcomes for this patient population. Many ongoing clinical trials use specific genetic mutations or histologic status to determine the combination of targeted therapies and RT, as well as to determine the optimal chemoradiotherapy platforms. Additionally, use of modern RT techniques has improved outcomes for some patients with limited metastatic disease, thereby prompting further studies on how to best integrate aggressive management of oligometastases using RT with chemotherapeutic regimens.
局部晚期非小细胞肺癌(LA-NSCLC)是一种异质性疾病,包括 IIIA 期,对于某些患者,手术联合化疗和/或放射治疗(RT)是一种潜在的治疗方法,以及 IIIB 期,放化疗是标准治疗。系统细胞毒性和分子靶向治疗的最新进展以及放射治疗的技术创新有可能改善这一患者群体的预后。许多正在进行的临床试验使用特定的基因突变或组织学状态来确定靶向治疗和 RT 的联合,以及确定最佳的放化疗平台。此外,现代 RT 技术的应用改善了一些有限转移疾病患者的预后,从而促使进一步研究如何最好地将 RT 联合化疗方案积极治疗寡转移。